000278567 001__ 278567
000278567 005__ 20250601001317.0
000278567 0247_ $$2doi$$a10.1038/s41531-025-00979-0
000278567 0247_ $$2pmid$$apmid:40346062
000278567 0247_ $$2pmc$$apmc:PMC12064827
000278567 0247_ $$2altmetric$$aaltmetric:177026103
000278567 037__ $$aDZNE-2025-00600
000278567 041__ $$aEnglish
000278567 082__ $$a610
000278567 1001_ $$00000-0002-7553-2111$$aRöttgen, Sinah$$b0
000278567 245__ $$aThe prodromal individuals' perspective on active recruitment for early detection of α-synucleinopathies.
000278567 260__ $$a[London]$$bSpringer Nature$$c2025
000278567 3367_ $$2DRIVER$$aarticle
000278567 3367_ $$2DataCite$$aOutput Types/Journal article
000278567 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1748427554_4359
000278567 3367_ $$2BibTeX$$aARTICLE
000278567 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000278567 3367_ $$00$$2EndNote$$aJournal Article
000278567 520__ $$aOnly the timely detection of individuals with incipient α-synucleinopathies can pave the way for developing disease-modifying therapies. Our aim was to explore the views of individuals with isolated REM sleep behavior disorder (iRBD), actively recruited from the general population, on the ethical justifiability of active recruitment and their experiences with risk disclosure. This mixed-methods study surveyed individuals with iRBD, confirmed by video-polysomnography, utilizing an interdisciplinary-developed online questionnaire. Of 99 invited individuals, 75 (75.8%) answered the survey. While 55.6% experienced the information on the increased risk as burdensome, 63.9% supported risk disclosure if consent had been obtained beforehand. Almost all individuals (96.2%) regarded our active recruitment method as appropriate, and 86.7% indicated they would participate again. Open-text responses indicated that key motivations included access to information and care, and contributing to research progress. This well-received recruitment strategy could serve as a model for future screening initiatives in α-synucleinopathy research.
000278567 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000278567 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000278567 7001_ $$0P:(DE-2719)2811829$$aSchäffer, Eva$$b1
000278567 7001_ $$00000-0002-5989-0744$$aRogge, Annette$$b2
000278567 7001_ $$aHartung, Ramona$$b3
000278567 7001_ $$0P:(DE-2719)9003179$$aKufer, Konstantin$$b4$$udzne
000278567 7001_ $$00000-0002-8230-1856$$aFink, Gereon R$$b5
000278567 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b6
000278567 7001_ $$00000-0001-5858-7762$$aOphey, Anja$$b7
000278567 7001_ $$0P:(DE-2719)9003277$$aSommerauer, Michael$$b8$$eLast author$$udzne
000278567 773__ $$0PERI:(DE-600)2819218-7$$a10.1038/s41531-025-00979-0$$gVol. 11, no. 1, p. 121$$n1$$p121$$tnpj Parkinson's Disease$$v11$$x2373-8057$$y2025
000278567 8564_ $$uhttps://pub.dzne.de/record/278567/files/DZNE-2025-00600%20SUP.pdf
000278567 8564_ $$uhttps://pub.dzne.de/record/278567/files/DZNE-2025-00600.pdf$$yOpenAccess
000278567 8564_ $$uhttps://pub.dzne.de/record/278567/files/DZNE-2025-00600%20SUP.pdf?subformat=pdfa$$xpdfa
000278567 8564_ $$uhttps://pub.dzne.de/record/278567/files/DZNE-2025-00600.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000278567 909CO $$ooai:pub.dzne.de:278567$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000278567 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003179$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000278567 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003277$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000278567 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000278567 9141_ $$y2025
000278567 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-11
000278567 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000278567 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-10T15:43:48Z
000278567 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-10T15:43:48Z
000278567 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000278567 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-10T15:43:48Z
000278567 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNPJ PARKINSONS DIS : 2022$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-11
000278567 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-11
000278567 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x0
000278567 9201_ $$0I:(DE-2719)1011302$$kAG Wüllner$$lBiomarker Parkinson's Disease$$x1
000278567 980__ $$ajournal
000278567 980__ $$aVDB
000278567 980__ $$aUNRESTRICTED
000278567 980__ $$aI:(DE-2719)1013020
000278567 980__ $$aI:(DE-2719)1011302
000278567 9801_ $$aFullTexts